drugset / Trial / NCT03822871
A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer
Phase 1
Completed
17 enrolled
Cancer Targeted Technology
National Cancer Institute (NCI) · collabUniversity of California, San Francisco · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to find the highest dose level of study drug, CTT1403, that can be safely administered to patients with metastatic castration resistant prostate cancer (mCRPC).
Timeline
- Start
- 2019-04-01
- Primary completion
- 2022-10-28
- Completion
- 2023-02-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-PSMA-11 | Diagnostic / imaging agent | — | — |
| Subject | CTT1057 | Small molecule | — | — |
| Subject | CTT1403 | Unknown | 750 mbq | — |
| Subject | CTT1403 | Unknown | 2000 mbq | — |
| Subject | CTT1403 | Unknown | 3000 mbq | — |
| Subject | CTT1403 | Unknown | 9000 mbq | — |